参考文献
1. Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47-62.
2. Church MK, Kolkhir P, Metz M, Maurer M. The role and relevance of mast cells in urticaria. Immunol Rev. 2018;282(1):232-247.
3. Choi BY, Ye YM. Role of Platelet-Activating Factor in the Pathogenesis of Chronic Spontaneous Urticaria. Int J Mol Sci. 2024;25(22):12143. Published 2024 Nov 12.
4. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819-1831.
5. Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57. Published 2018 Feb 19.
6. Benoit RY, Loshi S, Moore CS. Bruton's Tyrosine Kinase-Going Beyond the B Cell. Immunology. 2026;178(4):545-560.
7. Pulz R, Angst D, Cenni B. Next generation Bruton's tyrosine kinase inhibitors - characterization of in vitro potency and selectivity. Eur J Pharmacol. 2025;1002:177747.
8. Bernstein JA, Maurer M, Saini SS. BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2024;153(5):1229-1240.
9. Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J Med Chem. 2020;63(10):5102-5118.
10. Corrionero A, Zhang X, Alfonso P, et al. An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. ACS Pharmacol Transl Sci. 2025;8(12):4312-4325. Published 2025 Nov 18.
11. Kaul M, End P, Cabanski M, et al. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci. 2021;14(5):1756-1768.
12. Poster presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, Philadelphia, PA, February 27–March 2, 2026.
13. Maurer M, et al. Presented at EADV Congress 2024, 25-28 September; Amsterdam. Abstract P3625.
14. Saini S, et al. Oral presented at Maui Derm Hawaii 2025. January 20-24, 2025, Maui, Hawaii.
15. EAACI 2025_REMIX 1&2_Angioedema_Abstract_13JAN2025_Abstract 000816
16. Effect of remibrutinib on Sleep and Daily Activities in Patients With Chronic Spontaneous Urticaria (CSU) up to Week 52 in the REMIX-1/-2 studies.AAD 2025. Poster ID: 62278
17. Zuberbier T, Abdul Latiff A H, Abuzakouk M, et al. The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria[J]. Allergy, 2026, 0(0): 1-51.
18. Reed J, et al. Remibrutinib improves CSU independent of baseline IgE levels: phase 3 REMIX studies. EAACI. 2025.
19. Mosnaim G, et al. Poster presented at: American Academy of Allergy, Asthma & Immunology (AAAAI); 23-26 February 2024; Washington, DC.
20. Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025;392(10):984-994.
21. FC04_EADV 2024_REMIX Wk52 Primary Analysis_Oral Presentation_Final Submitted_23SEP2024.